Mrs Georgina Gardner
(she/her)
Clinical Trials Manager
- GardnerG@cardiff.ac.uk
- Neuadd Meirionnydd, Room Floor 6, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS
Overview
I have worked within Oncology for 22 years. My background experience is working within the Clinical Trials Unit at Velindre Cancer Centre for 10 years, setting up various oncology studies with the Research Team. This provided me with a wealth of knowledge that I could transfere over to CTR. I have been employed with CTR for 12 years. Firstly as a Data Manager and then promoted to Trial Manager in 2014.
During my time I have worked on various studies both CTIMP and non-STIMP such as, RT3VIN, SCOPE, CONSCOP, CONSCOP2, VIM and PIN.
My main area of interest is screening and prevention. I am currently working on the CONSCOP2 study, which is looking to improve the effectiveness of the bowel cancer screening program in reducing the incidence and mortality from proximal colon cancer by comparing a standard colonscopys Vs chromocolonoscopy.
Having experienced setting up clinical trials in a hospital enviroment with the research nurses and in the University setting gives me a broad knowledge on how best to approach sites, work with them and build good relationships across all professions.
Publication
2022
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al. 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48, article number: 101432. (10.1016/j.eclinm.2022.101432)
2019
- Hurt, C. et al. 2019. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial. Lancet Gastroenterology and Hepatology 4(5), pp. 364-375. (10.1016/S2468-1253(19)30035-4)
Articles
- Fennell, D. A. et al. 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52, article number: 101595. (10.1016/j.eclinm.2022.101595)
- Fennell, D. A. et al. 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48, article number: 101432. (10.1016/j.eclinm.2022.101432)
- Hurt, C. et al. 2019. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial. Lancet Gastroenterology and Hepatology 4(5), pp. 364-375. (10.1016/S2468-1253(19)30035-4)
Research
I have managed the following studies which are now closed.
VIM - A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma
PIN - A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer
CONSCOP - Feasability study in reduction of right sided bowel cancer through contrast enhanced colnonoscopy
I currently manage the following clinical study within the Centre for Trials Research:
CONSCOP2 - Randomised controlled trial of contrast enhanced colonoscopy in the reduction of right sided bowel cancer
Papers and Abstracts
THELANCETGASTROHEP-D-19-00011R2, Feasibility and economic evaluation of chromocolonoscopy for detection of proximal serrated neoplasia: a randomised controlled trial within a population based colorectal cancer screening programme (the CONSCOP study)
ASCO Abstract #305579
PIN - A randomised phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.
ASCO Annual Meeting (June 4 - June 8, 2021):
Abstract ID #: 333139 Title: VIM - A randomised phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma.
Biography
Clinical Trials Manager, WCTU November 2014 to date
Solid Tumour Portfolio developer, NISCHR, WCTU July 2013 – November 2014
Data Manager, Wales Cancer Trials Unit December 2008 – July 2013
Research administrator, Velindre NHS Trust 1998 - 2008